



Copy 8-#10

PATENT  
Attorney Docket No.: SALK1590-3  
(088802-2454)

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING GROUP 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HEINEMANN et al.  
Title: NEURONAL NICOTINIC  
ACETYLCHOLINE RECEPTOR  
COMPOSITIONS

Appl. No.: 09/580,462

Filing Date: May 26, 2000

Examiner: J. Ulm

Art Unit: 1646

<p><b>CERTIFICATION UNDER 37 CFR § 1.8</b> I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on the date below, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231</p> <p><u>Stephen E. Reiter, Reg. No. 31,192</u> (Printed Name) <u>[Signature]</u> (Signature) <u>10/3/02</u> (Date of Deposit)</p>
--

RECEIVED

DEC 09 2002

TECH CENTER 1600/2900

AMENDMENT

Box AF  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Responsive to the Office Action dated July 3, 2002 (Paper No. 9), please consider the following amendments and remarks.

IN THE CLAIMS

Please cancel claims 5-6, 8-9, 11-12 and 14-33, and add new claims 34-44 as follows. All claims, as they will stand upon entry of the amendments submitted herewith, are attached hereto as Appendix A.

34 (New). A substantially pure polynucleotide comprising DNA encoding a beta2 subunit of a neuronal acetylcholine receptor, wherein said DNA has greater than 64% sequence homology to the nucleotide sequence set forth in Figures 7B(1), 7B(2) and 7B(3), and

wherein said beta2 subunit has one or more functional properties selected from the group consisting of: